All the news Showing 10 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New EASL hepatitis C recommendations emphasise simplicity Liz Highleyman / 23 April 2018 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment recommendations at the 2018 International Liver Congress this month in Paris. The guidelines are available online in ... Sofosbuvir/ledipasvir for 8 weeks cures acute HCV in people with HIV Liz Highleyman / 28 November 2017 An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according ... Hepatitis C halved in Spanish people living with HIV in one year due to treatment Keith Alcorn / 27 October 2017 Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid, reported on Friday at the ... Hepatitis C treatment is effective and feasible in Africa Liz Highleyman / 25 July 2017 Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to a presentation yesterday at the ... Sofosbuvir plus ribavirin cures teens with genotype 2 or 3 hepatitis C Liz Highleyman / 05 June 2017 A two-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course ... Indonesian buyers club helps people obtain generic hepatitis C treatment Liz Highleyman / 30 May 2017 A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high cure rate, according to a ... Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman / 02 May 2017 Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination ... Hepatitis C treatment can be provided successfully at syringe programme sites Liz Highleyman / 18 April 2017 Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent ... FDA approves Harvoni and Sovaldi for adolescents with hepatitis C Liz Highleyman / 10 April 2017 The US Food and Drug Administration (FDA) on 7 April approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to 17 years. ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... ← First12345...25Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive